The role of somatostatin analogues in the treatment of neuroendocrine tumours

Molecular and Cellular Endocrinology

Volumn 286, Issue 1-2, 2008, Pages 238-250

  Grozinsky Glasberg, Simona ^a,b   Grossman, Ashley B ^a   Korbonits, Márta ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Neuroendocrine tumours; Octreotide; Somatostatin

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; DOTATOC Y 90; GALLIUM; INDIUM 111; INTERFERON; LUTETIUM; LUTETIUM 177; OCTREOTATE LU 177; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE IN 111; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE; YTTRIUM; YTTRIUM 90;

ADD ON THERAPY; BRONCHUS CARCINOID; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOID SYNDROME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; ENTEROCHROMAFFIN LIKE CELL; GASTRINOMA; GLUCAGONOMA; HUMAN; INSULINOMA; ISOTOPE LABELING; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; SOMATOSTATINOMA; STOMACH CARCINOID; STOMACH TUMOR; SURGICAL TECHNIQUE; THYMOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY; TUMOR GROWTH; TUMOR REGRESSION; ZOLLINGER ELLISON SYNDROME;

EID: 43749108350     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.10.006     Document Type: Review

References (166)

1. G. Akerstrom Management of carcinoid tumors of the stomach, duodenum, and pancreas World J. Surg. 20 1996 173 182
2. S. Angeletti V.D. Corleto O. Schillaci M. Marignani B. Annibale A. Moretti G. Silecchia F. Scopinaro N. Basso C. Bordi F.G. Delle Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours Gut 42 1998 792 794
3. R. Arnold M.E. Trautmann W. Creutzfeldt R. Benning M. Benning C. Neuhaus R. Jurgensen K. Stein H. Schafer C. Bruns H.J. Dennler Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours Gut 38 1996 430 438
4. R. Arnold B. Simon M. Wied Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review Digestion 62 Suppl. 1 2000 84 91
5. M.G. Arrigoni L.B. Woolner P.E. Bernatz Atypical carcinoid tumors of the lung J. Thorac. Cardiovasc. Surg. 64 1972 413 421
6. D. Astuti N. Hart-Holden F. Latif F. Lalloo G.C. Black C. Lim A. Moran A.B. Grossman S.V. Hodgson A. Freemont R. Ramsden C. Eng D.G. Evans E.R. Maher Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility Clin. Endocrinol. (Oxf) 59 2003 728 733
7. D. Astuti M. Morris C. Krona F. Abel D. Gentle T. Martinsson P. Kogner H.P. Neumann R. Voutilainen C. Eng P. Rustin F. Latif E.R. Maher Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma Br. J. Cancer 91 2004 1835 1841
8. M.B. Beasley E. Brambilla W.D. Travis The 2004 World Health Organization classification of lung tumors Semin. Roentgenol. 40 2005 90 97
9. S.R. Bloom J.M. Polak A.G. Pearse Vasoactive intestinal peptide and watery-diarrhoea syndrome Lancet 2 1973 14 16
10. E. Boix A. Pico R. Pinedo I. Aranda K. Kovacs Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour Clin. Endocrinol. (Oxf) 57 2002 131 134
11. E.L. Bravo Pheochromocytoma Cardiol. Rev. 10 2002 44 50
12. E.L. Bravo R. Tagle Pheochromocytoma: state-of-the-art and future prospects Endocr. Rev. 24 2003 539 553
13. C. Bruns I. Lewis U. Briner G. Meno-Tetang G. Weckbecker SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur. J. Endocrinol. 146 2002 707 716
14. C. Capella P.U. Heitz H. Hofler E. Solcia G. Kloppel Revised classification of neuroendocrine tumours of the lung, pancreas and gut Virchows Arch. 425 1995 547 560
15. M.E. Caplin J.R. Buscombe A.J. Hilson A.L. Jones A.F. Watkinson A.K. Burroughs Carcinoid tumour Lancet 352 1998 799 805
16. A. Carretta G. Chiesa P. Magnani C. Songini G. Melloni P. Zannini A. Grossi Imaging of bronchial carcinoid tumors associated to Cushing syndrome with 111In-Octreoscan scintigraphy and immunoscintigraphy with anti-chromogranin monoclonal antibodies. Report of two cases J. Cardiovasc. Surg. (Torino) 38 1997 191 194
17. R. Casadei P. Tomassetti C. Rossi M. la Donna M. Migliori D. Marrano Treatment of metastatic glucagonoma to the liver: case report and literature review Ital. J. Gastroenterol. Hepatol. 31 1999 308 312
18. A. Cascon S. Ruiz-Llorente M.F. Fraga R. Leton D. Telleria J. Sastre J.J. Diez G. Martinez Diaz-Guerra J.A. Diaz Perez J. Benitez M. Esteller M. Robledo Genetic and epigenetic profile of sporadic pheochromocytomas J. Med. Genet. 41 2004 e30
19. M. Castellano L. Mori M. Giacche E. Agliozzo R. Tosini A. Panarotto C. Cappelli P. Mulatero D. Cumetti F. Veglio E. Agabiti-Rosei Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients Ann. NY Acad. Sci. 1073 2006 156 165
20. J.A. Chan M.H. Kulke Emerging therapies for the treatment of patients with advanced neuroendocrine tumors Expert. Opin. Emerg. Drugs 12 2007 253 270
21. M.A. Chastain The glucagonoma syndrome: a review of its features and discussion of new perspectives Am. J. Med. Sci. 321 2001 306 320
22. S. Corbetta M. Peracchi V. Cappiello A. Lania E. Lauri L. Vago P. Beck-Peccoz A. Spada Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma J. Clin. Endocrinol. Metab. 88 2003 3117 3120
23. D.G. Davila W.F. Dunn H.D. Tazelaar P.C. Pairolero Bronchial carcinoid tumors Mayo Clin. Proc. 68 1993 795 803
24. K.P. Davis L.K. Hartmann G.L. Keeney H. Shapiro Primary ovarian carcinoid tumors Gynecol. Oncol. 61 1996 259 265
25. W.W. de Herder S.W. Lamberts Somatostatin and somatostatin analogues: diagnostic and therapeutic uses Curr. Opin. Oncol. 14 2002 53 57
26. W.W. de Herder L.J. Hofland A.J. van der Lely S.W. Lamberts Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours Endocr. Relat Cancer 10 2003 451 458
27. W.W. de Herder D.J. Kwekkeboom R.A. Feelders M.O. van Aken S.W. Lamberts A.J. van der Lely E.P. Krenning Somatostatin receptor imaging for neuroendocrine tumors Pituitary 9 2006 243 248
28. W.W. de Herder B. Niederle J.Y. Scoazec S. Pauwels G. Kloppel M. Falconi D.J. Kwekkeboom K. Oberg B. Eriksson B. Wiedenmann G. Rindi D. O’Toole D. Ferone Well-differentiated pancreatic tumor/carcinoma: insulinoma Neuroendocrinology 84 2006 183 188
29. M. de Jong W.A. Breeman R. Valkema B.F. Bernard E.P. Krenning Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs J. Nucl. Med. 46 Suppl. 1 2005 13S 17S
30. M. Di Bartolomeo E. Bajetta R. Buzzoni L. Mariani C. Carnaghi L. Somma N. Zilembo A. di Leo Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group Cancer 77 1996 402 408
31. M. Dusmet M.F. McKneally Bronchial and thymic carcinoid tumors: a review Digestion 55 Suppl. 3 1994 70 76
32. S. Ekeblad B. Nilsson M.H. Lejonklou T. Johansson P. Stalberg O. Nilsson H. Ahlman B. Skogseid Gastrointestinal stromal tumors express the orexigen ghrelin Endocr. Relat. Cancer 13 2006 963 970
33. B. Eriksson K. Oberg Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook Ann. Oncol. 10 Suppl. 2 1999 S31 S38
34. B. Eriksson J. Renstrup H. Imam K. Oberg High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects Ann. Oncol. 8 1997 1041 1044
35. D.B. Evans J.M. Skibber J.E. Lee K.R. Cleary J.A. Ajani R.F. Gagel R.V. Sellin C.J. Fenoglio R.C. Merrell R.C. Hickey Nonfunctioning islet cell carcinoma of the pancreas Surgery 114 1993 1175 1181
36. S. Faiss U. Rath U. Mansmann D. Caird N. Clemens E.O. Riecken B. Wiedenmann Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors Digestion 60 1999 469 476
37. P. Ferolla A. Falchetti P. Filosso P. Tomassetti G. Tamburrano N. Avenia G. Daddi F. Puma R. Ribacchi F. Santeusanio G. Angeletti M.L. Brandi Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series J. Clin. Endocrinol. Metab. 90 2005 2603 2609
38. D. Ferone A. Saveanu M.D. Culler M. Arvigo A. Rebora F. Gatto F. Minuto P. Jaquet Novel chimeric somatostatin analogs: facts and perspectives Eur. J. Endocrinol. 156 2007 23 28
39. P.L. Filosso E. Ruffini A. Oliaro E. Papalia G. Donati O. Rena Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide Eur. J. Cardiothorac. Surg. 21 2002 913 917
40. M. Fjalling P. Andersson E. Forssell-Aronsson J. Gretarsdottir V. Johansson L.E. Tisell B. Wangberg O. Nilsson G. Berg A. Michanek G. Lindstedt H. Ahlman Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome J. Nucl. Med. 37 1996 1519 1521
41. M. Frank K.J. Klose M. Wied N. Ishaque C. Schade-Brittinger R. Arnold Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors Am. J. Gastroenterol. 94 1999 1381 1387
42. V. Fykse A.K. Sandvik G. Qvigstad S.E. Falkmer U. Syversen H.L. Waldum Treatment of ECL cell carcinoids with octreotide LAR Scand. J. Gastroenterol. 39 2004 621 628
43. R.B. Ganim J.A. Norton Recent advances in carcinoid pathogenesis, diagnosis and management Surg. Oncol. 9 2000 173 179
44. d.l.T. Garcia J.A. Wass H.E. Turner Antiangiogenic effects of somatostatin analogues Clin. Endocrinol. (Oxf) 57 2002 425 441
45. A.A. Ghaferi K.A. Chojnacki W.D. Long J.L. Cameron C.J. Yeo Pancreatic VIPomas: subject review and one institutional experience J. Gastrointest. Surg. 2007
46. F. Gibril Y.J. Chen D.S. Schrump A. Vortmeyer Z. Zhuang I.A. Lubensky J.C. Reynolds A. Louie L.K. Entsuah K. Huang B. Asgharian R.T. Jensen Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1 J. Clin. Endocrinol. Metab. 88 2003 1066 1081
47. D. Giuffrida H. Gharib Current diagnosis and management of medullary thyroid carcinoma Ann. Oncol. 9 1998 695 701
48. R.E. Goldstein J.A. O’Neill Jr. G.W. Holcomb III W.M. Morgan III W.W. Neblett III J.A. Oates N. Brown J. Nadeau B. Smith D.L. Page N.N. Abumrad H.W. Scott Jr. Clinical experience over 48 years with pheochromocytoma Ann. Surg. 229 1999 755 764
49. D.B. Gough G.B. Thompson T.B. Crotty J.H. Donohue L.K. Kvols J.A. Carney C.S. Grant D.M. Nagorney Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia World J. Surg. 18 1994 473 479
50. D. Granberg E. Wilander M. Stridsberg G. Granerus B. Skogseid K. Oberg Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids Gut 43 1998 223 228
51. D. Granberg B. Eriksson E. Wilander P. Grimfjard M.L. Fjallskog K. Oberg B. Skogseid Experience in treatment of metastatic pulmonary carcinoid tumors Ann. Oncol. 12 2001 1383 1391
52. D. Granberg A. Sundin E.T. Janson K. Oberg B. Skogseid J.E. Westlin Octreoscan in patients with bronchial carcinoid tumours Clin. Endocrinol. (Oxf) 59 2003 793 799
53. S. Grozinsky-Glasberg G. Franchi M. Teng C.A. Leontiou A. Ribeiro de Oliveira Jr. P. Dalino N. Salahuddin M. Korbonits A.B. Grossman Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuroendocrine tumor cell line Neuroendocrinology 87 2008 168 181
54. M. Gugger B. Waser A. Kappeler A. Schonbrunn J.C. Reubi Immunohistochemical localization of somatostatin receptor sst2A in human gut and lung tissue: possible implications for physiology and carcinogenesis Ann. NY Acad. Sci. 1014 2004 132 136
55. P.R. Hearn M. Ahmed N.J. Woodhouse The use of SMS 201–995 (somatostatin analogue) in insulinomas. Additional case report and literature review Horm. Res. 29 1988 211 213
56. P.R. Hearn C.L. Reynolds K. Johansen N.J. Woodhouse Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201–995 (sandostatin) Clin. Endocrinol. (Oxf) 28 1988 181 185
57. A. Heppeler S. Froidevaux A.N. Eberle H.R. Maecke Receptor targeting for tumor localisation and therapy with radiopeptides Curr. Med. Chem. 7 2000 971 994
58. I. Heron F. Thomas M. Dero A. Gancel J.M. Ruiz B. Schatz J.M. Kuhn Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly J. Clin. Endocrinol. Metab. 76 1993 721 727
59. H. Imam B. Eriksson A. Lukinius E.T. Janson P.G. Lindgren E. Wilander K. Oberg Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs Acta Oncol. 36 1997 607 614
60. C. Invitti M.I. De G.B. Bolla G.F. Pecori E. Maestri G. Leonetti F. Cavagnini Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors Horm. Res. 40 1993 156 160
61. E.T. Janson K. Oberg Neuroendocrine tumors–somatostatin receptor expression and somatostatin analog treatment Cancer Chemother. Biol. Response Modif. 21 2003 535 546
62. E.T. Janson M. Stridsberg A. Gobl J.E. Westlin K. Oberg Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies Cancer Res. 58 1998 2375 2378
63. E.T. Janson K.M. Kalkner B. Eriksson J.E. Westlin K. Oberg Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors Nucl. Med. Biol. 26 1999 877 882
64. R.T. Jensen Gastrointestinal endocrine tumours. Gastrinoma Baillieres Clin. Gastroenterol. 10 1996 603 643
65. R.T. Jensen Gastrinomas: advances in diagnosis and management Neuroendocrinology 80 Suppl. 1 2004 23 27
66. G. Kaltsas M. Korbonits E. Heintz J.J. Mukherjee P.J. Jenkins S.L. Chew R. Reznek J.P. Monson G.M. Besser R. Foley K.E. Britton A.B. Grossman Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors J. Clin. Endocrinol. Metab. 86 2001 895 902
67. G.A. Kaltsas D. Papadogias P. Makras A.B. Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer 12 2005 683 699
68. E. Kebebew P.H. Ituarte A.E. Siperstein Q.Y. Duh O.H. Clark Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems Cancer 88 2000 1139 1148
69. U. Koehler S. Meyer S. Schaefer D. Ivan P.H. Kann Tumor regression in a nonfunctioning pancreatic neuroendocrine tumor during somatostatin analogue treatment Exp. Clin. Endocrinol. Diabetes 115 2007 10.1055/s-2007-972504
70. L. Kolby G. Persson S. Franzen B. Ahren Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours Br. J. Surg. 90 2003 687 693
71. D. Kopf A. Bockisch H. Steinert K. Hahn J. Beyer H.P. Neumann J. Hensen H. Lehnert Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma Clin. Endocrinol. (Oxf) 46 1997 39 44
72. N. Koriyama M. Kakei K. Yaekura H. Okui T. Yamashita H. Nishimura S. Matsushita C. Tei Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies Horm. Res. 53 2000 46 50
73. E.P. Krenning M. de Jong P.P. Kooij W.A. Breeman W.H. Bakker W.W. de Herder C.H. Van Eijck D.J. Kwekkeboom F. Jamar S. Pauwels R. Valkema Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy Ann. Oncol. 10 Suppl. 2 1999 S23 S29
74. M.H. Kulke R.J. Mayer Carcinoid tumors N. Engl. J. Med. 340 1999 858 868
75. L.K. Kvols C.G. Moertel M.J. O’Connell A.J. Schutt J. Rubin R.G. Hahn Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue N. Engl. J. Med. 315 1986 663 666
76. L. Kvols K. Oberg W. de Herder L. Anthony J. Glusman L. Tran B. Wiedenmann Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR J. Clin. Oncol. 23 2005 8024
77. D.J. Kwekkeboom J.J. Teunissen W.H. Bakker P.P. Kooij W.W. de Herder R.A. Feelders C.H. Van Eijck J.P. Esser B.L. Kam E.P. Krenning Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors J. Clin. Oncol. 23 2005 2754 2762
78. M. Lamarre-Cliche A.P. Gimenez-Roqueplo E. Billaud E. Baudin J.P. Luton P.F. Plouin Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma Clin. Endocrinol. (Oxf) 57 2002 629 634
79. S.W. Lamberts W.H. Bakker J.C. Reubi E.P. Krenning Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs Metabolism 39 1990 152 155
80. S.W. Lamberts W.W. de Herder L.J. Hofland Somatostatin analogs in the diagnosis and treatment of cancer Trends Endocrinol. Metab. 13 2002 451 457
81. S.W. Lamberts A.J. van der Lely L.J. Hofland New somatostatin analogs: will they fulfil old promises? Eur. J. Endocrinol. 146 2002 701 705
82. G. Lupoli E. Cascone F. Arlotta G. Vitale L. Celentano M. Salvatore G. Lombardi Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide Cancer 78 1996 1114 1118
83. C. Mahler J. Verhelst M. de Longueville A. Harris Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide Clin. Endocrinol. (Oxf) 33 1990 261 269
84. L. Mansi P.F. Rambaldi N. Panza D. Esposito V. Esposito V. Pastore Diagnosis and radioguided surgery with 111In-pentetreotide in a patient with paraneoplastic Cushing's syndrome due to a bronchial carcinoid Eur. J. Endocrinol. 137 1997 688 690
85. D.J. Marsh D.L. Learoyd B.G. Robinson Medullary thyroid carcinoma: recent advances and management update Thyroid 5 1995 407 424
86. G. Matejka M. Toubeau A. Bernard Y. Belleville G. Vaillant J.M. Brun Thymic carcinoid tumor causing paraneoplastic Cushing syndrome. Diagnostic value of double-labelled tomoscintigraphy Presse Med. 25 1996 1201 1202
87. P.N. Maton Use of octreotide acetate for control of symptoms in patients with islet cell tumors World J. Surg. 17 1993 504 510
88. D.C. Metz D.B. Strader M. Orbuch P.D. Koviack K.M. Feigenbaum R.T. Jensen Use of omeprazole in Zollinger–Ellison syndrome: a prospective nine-year study of efficacy and safety Aliment. Pharmacol. Ther. 7 1993 597 610
89. A.N. Mhatre Y. Li L. Feng A. Gasperin A.K. Lalwani SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas Clin. Genet. 66 2004 461 466
90. E. Modigliani R. Cohen S. Joannidis C. Siame-Mourot J.M. Guliana G. Charpentier D. Cassuto P.M. Bentata A. Tabarin P. Roger Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma Clin. Endocrinol. (Oxf) 36 1992 183 186
91. I.M. Modlin M.D. Shapiro M. Kidd Siegfried Oberndorfer: origins and perspectives of carcinoid tumors Hum. Pathol. 35 2004 1440 1451
92. C.G. Moertel Karnofsky memorial lecture. An odyssey in the land of small tumors J. Clin. Oncol. 5 1987 1502 1522
93. C.A. Moran S. Suster Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases Am. J. Clin. Pathol. 114 2000 100 110
94. J. Mundschenk N. Unger S. Schulz V. Hollt S. Schulz R. Steinke H. Lehnert Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy J. Clin. Endocrinol. Metab. 88 2003 5150 5157
95. C. Neumayer A. Moritz R. Asari A. Weinhausel T. Holzenbein G. Kretschmer B. Niederle O.A. Haas Novel SDHD germ-line mutations in pheochromocytoma patients Eur. J. Clin. Invest. 37 2007 544 551
96. O. Nilsson L. Kolby B. Wangberg A. Wigander H. Billig L. William-Olsson M. Fjalling E. Forssell-Aronsson H. Ahlman Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours Br. J. Cancer 77 1998 632 637
97. K. Oberg Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment Curr. Opin. Oncol. 14 2002 38 45
98. K. Oberg Future aspects of somatostatin-receptor-mediated therapy Neuroendocrinology 80 Suppl. 1 2004 57 61
99. K. Oberg Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment Curr. Opin. Oncol. 17 2005 386 391
100. K. Oberg B. Eriksson Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours Best. Pract. Res. Clin. Endocrinol. Metab. 19 2005 265 276
101. K. Oberg I. Norheim E. Theodorsson Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide Acta Oncol. 30 1991 503 507
102. T.M. O’Dorisio H.S. Mekhjian T.S. Gaginella Medical therapy of VIPomas Lost Data 18 1989 545 556
103. D. O’Toole M. Ducreux G. Bommelaer J.L. Wemeau O. Bouche F. Catus J. Blumberg P. Ruszniewski Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance Cancer 88 2000 770 776
104. M. Papotti U. Kumar M. Volante C. Pecchioni Y.C. Patel Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid Clin. Endocrinol. (Oxf) 54 2001 641 649
105. M. Papotti M. Bongiovanni M. Volante E. Allia S. Landolfi L. Helboe M. Schindler S.L. Cole G. Bussolati Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis Virchows Arch. 440 2002 461 475
106. Y.C. Patel Somatostatin and its receptor family Front. Neuroendocrinol. 20 1999 157 198
107. Y.C. Patel K.K. Murthy E.E. Escher D. Banville J. Spiess C.B. Srikant Mechanism of action of somatostatin: an overview of receptor function and studies of the molecular characterization and purification of somatostatin receptor proteins Metabolism 39 1990 63 69
108. M. Phlipponneau M. Nocaudie J. Epelbaum Y. De Keyzer J.D. Lalau X. Marchandise X. Bertagna Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor J. Clin. Endocrinol. Metab. 78 1994 20 24
109. U. Plockinger G. Rindi R. Arnold B. Eriksson E.P. Krenning W.W. de Herder A. Goede K. Oberg J.C. Reubi O. Nilsson F.G. Delle P. Ruszniewski H. Ahlman B. Wiedenmann Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS) Neuroendocrinology 80 2004 394 424
110. R. Prommegger R. Bale C. Ensinger T. Sauper C. Profanter M. Knoflach R. Moncayo Gastric carcinoid type I tumour: new diagnostic and therapeutic method Eur. J. Gastroenterol. Hepatol. 15 2003 705 707
111. F. Raue German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2 Langenbecks Arch. Surg. 383 1998 334 336
112. J.C. Reubi Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment Neuroendocrinology 80 Suppl. 1 2004 51 56
113. J.C. Reubi L. Kvols E. Krenning S.W. Lamberts Distribution of somatostatin receptors in normal and tumor tissue Metabolism 39 1990 78 81
114. J.C. Reubi J.C. Schaer B. Waser G. Mengod Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization Cancer Res. 54 1994 3455 3459
115. J.C. Reubi A. Kappeler B. Waser J. Laissue R.W. Hipkin A. Schonbrunn Immunohistochemical localization of somatostatin receptors sst2A in human tumors Am. J. Pathol. 153 1998 233 245
116. G. Rindi C. Bordi S. Rappel S. La Rosa M. Stolte E. Solcia Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior World J. Surg. 20 1996 168 172
117. G. Rindi C. Azzoni S. La Rosa C. Klersy D. Paolotti S. Rappel M. Stolte C. Capella C. Bordi E. Solcia ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis Gastroenterology 116 1999 532 542
118. G. Rindi V. Villanacci A. Ubiali Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors Digestion 62 Suppl. 1 2000 19 26
119. J. Rosai E. Higa Mediastinal endocrine neoplasm, of probable thymic origin, related to carcinoid tumor. Clinicopathologic study of 8 cases Cancer 29 1972 1061 1074
120. J. Rosai E. Higa J. Davie Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association Cancer 29 1972 1075 1083
121. P.K. Roy D.J. Venzon H. Shojamanesh A. Abou-Saif P. Peghini J.L. Doppman F. Gibril R.T. Jensen Zollinger–Ellison syndrome. Clinical presentation in 261 patients Medicine (Baltimore) 79 2000 379 411
122. J. Rubin J. Ajani W. Schirmer A.P. Venook R. Bukowski R. Pommier L. Saltz P. Dandona L. Anthony Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome J. Clin. Oncol. 17 1999 600 606
123. P. Ruszniewski S. Ish-Shalom M. Wymenga D. O’Toole R. Arnold P. Tomassetti N. Bax M. Caplin B. Eriksson B. Glaser M. Ducreux C. Lombard-Bohas W.W. de Herder F.G. Delle N. Reed J.F. Seitz E. Van Cutsem A. Grossman P. Rougier W. Schmidt B. Wiedenmann Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide Neuroendocrinology 80 2004 244 251
124. L. Saltz B. Trochanowski M. Buckley B. Heffernan D. Niedzwiecki Y. Tao D. Kelsen Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors Cancer 72 1993 244 248
125. R. Schlaghecke G. Kreuzpaintner K.F. Burrig E. Juli H.K. Kley Cushing's syndrome due to ACTH-production of an ovarian carcinoid Klin. Wochenschr. 67 1989 640 644
126. M. Schlumberger C. Gicquel J. Lumbroso F. Tenenbaum E. Comoy J. Bosq E. Fonseca P.P. Ghillani B. Aubert J.P. Travagli Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases J. Endocrinol. Invest. 15 1992 631 642
127. S. Schulz J. Schmitt C. Quednow A. Roessner W. Weise Immunohistochemical detection of somatostatin receptors in human ovarian tumors Gynecol. Oncol. 84 2002 235 240
128. C.J. Schwartz D.V. Kimberg H.E. Sheerin M. Field S.I. Said Vasoactive intestinal peptide stimulation of adenylate cyclase and active electrolyte secretion in intestinal mucosa J. Clin. Invest. 54 1974 536 544
129. F.J. Service M.M. McMahon P.C. O’Brien D.J. Ballard Functioning insulinoma—incidence, recurrence, and long-term survival of patients: a 60-year study Mayo Clin. Proc. 66 1991 711 719
130. B. Shapiro L.M. Fig Management of pheochromocytoma Endocrinol. Metab Clin. North Am. 18 1989 443 481
131. H. Shojamanesh F. Gibril A. Louie J.V. Ojeaburu S. Bashir A. Abou-Saif R.T. Jensen Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma Cancer 94 2002 331 343
132. J. Soga Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature Surg. Today 27 1997 892 901
133. J. Soga Y. Yakuwa Vipoma/diarrheogenic syndrome: a statistical evaluation of 241 reported cases J. Exp. Clin. Cancer Res. 17 1998 389 400
134. J. Soga Y. Yakuwa Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas J. Exp. Clin. Cancer Res. 18 1999 13 22
135. J. Soga T. Suzuki K. Yoshikawa H. Katoh Y. Tsuno T. Muto Carcinoid somatostatinoma of the duodenum Eur. J. Cancer 26 1990 1107 1108
136. J. Soga Y. Yakuwa M. Osaka Carcinoid syndrome: a statistical evaluation of 748 reported cases J. Exp. Clin. Cancer Res. 18 1999 133 141
137. E. Solcia G. Rindi D. Paolotti S. La Rosa C. Capella R. Fiocca Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract Ann. Oncol. 10 Suppl. 2 1999 S9 S15
138. Solcia, E., Klöppel, G., Sobin, H., 2000. Histological typing of endocrine tumours. World Health Organization International Histological Classification of Tumours.
139. Y. Tanaka H. Funahashi T. Imai T. Naruse K. Suzumura Y. Oda The effectiveness of administering a minimal dose of octreotide long-term prior to surgery for insulinoma: report of a case Surg. Today 30 2000 541 543
140. E.M. Tiensuu Janson H. Ahlstrom T. Andersson K.E. Oberg Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours Eur. J. Cancer A 28 1992 1647 1650
141. O. Tiffet A.G. Nicholson G. Ladas M.N. Sheppard P. Goldstraw A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus Chest 124 2003 141 146
142. P. Tomassetti M. Migliori G.C. Caletti P. Fusaroli R. Corinaldesi L. Gullo Treatment of type II gastric carcinoid tumors with somatostatin analogues N. Engl. J. Med. 343 2000 551 554
143. P. Tomassetti M. Migliori R. Corinaldesi L. Gullo Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR Aliment. Pharmacol. Ther. 14 2000 557 560
144. P. Tomassetti D. Campana L. Piscitelli E. Mazzotta E. Brocchi R. Pezzilli R. Corinaldesi Treatment of Zollinger–Ellison syndrome World J. Gastroenterol. 11 2005 5423 5432
145. W.D. Travis W. Rush D.B. Flieder R. Falk M.V. Fleming A.A. Gal M.N. Koss Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid Am. J. Surg. Pathol. 22 1998 934 944
146. A.V. Tsolakis G.M. Portela-Gomes M. Stridsberg L. Grimelius A. Sundin B.K. Eriksson K.E. Oberg E.T. Janson Malignant gastric ghrelinoma with hyperghrelinemia J. Clin. Endocrinol. Metab. 89 2004 3739 3744
147. B. Ueberberg H. Tourne A. Redman M.K. Walz K.W. Schmid K. Mann S. Petersenn Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumors and normal adrenal gland Horm. Metab. Res. 37 2005 722 728
148. R. Valkema M. de Jong W.H. Bakker W.A. Breeman P.P. Kooij P.J. Lugtenburg F.H. De Jong A. Christiansen B.L. Kam W.W. de Herder M. Stridsberg J. Lindemans G. Ensing E.P. Krenning Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience Semin. Nucl. Med. 32 2002 110 122
149. E. van der Harst W.W. de Herder H.A. Bruining H.J. Bonjer R.R. de Krijger S.W. Lamberts A.H. van de Meiracker F. Boomsma T. Stijnen E.P. Krenning F.T. Bosman D.J. Kwekkeboom [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas J. Clin. Endocrinol. Metab. 86 2001 685 693
150. C.H. van Eyck H.A. Bruining J.C. Reubi W.H. Bakker H.Y. Oei E.P. Krenning S.W. Lamberts Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors World J. Surg. 17 1993 444 447
151. D. Vergani L. Massironi F. Lombardi C. Fiorentini Carcinoid heart disease from ovarian primary presenting with acute pericarditis and biventricular failure Heart 80 1998 623 626
152. L. Verschoor P. Uitterlinden S.W. Lamberts E. Del Pozo On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma Clin. Endocrinol. (Oxf) 25 1986 555 560
153. D. Vezzosi A. Bennet P. Rochaix F. Courbon J. Selves B. Pradere L. Buscail C. Susini P. Caron Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies Eur. J. Endocrinol. 152 2005 757 767
154. A.I. Vinik S.T. Tsai A.R. Moattari P. Cheung F.E. Eckhauser K. Cho Somatostatin analogue (SMS 201–995) in the management of gastroenteropancreatic tumors and diarrhea syndromes Am. J. Med. 81 1986 23 40
155. A.I. Vinik M.K. McLeod L.M. Fig B. Shapiro R.V. Lloyd K. Cho Clinical features, diagnosis, and localization of carcinoid tumors and their management Lost Data 18 1989 865 896
156. I. Virgolini K. Britton J. Buscombe R. Moncayo G. Paganelli P. Riva In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin. Nucl. Med. 32 2002 148 155
157. G. Vitale P. Tagliaferri M. Caraglia E. Rampone A. Ciccarelli A.R. Bianco A. Abbruzzese G. Lupoli Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma J. Clin. Endocrinol. Metab 85 2000 983 988
158. F.E. von Eyben E. Grodum H.J. Gjessing C. Hagen H. Nielsen Metabolic remission with octreotide in patients with insulinoma J. Intern. Med. 235 1994 245 248
159. C. Waldherr M. Pless H.R. Maecke A. Haldemann J. Mueller-Brand The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study Ann. Oncol. 12 2001 941 945
160. W.H. Warren V.E. Gould Neuroendocrine tumors of the bronchopulmonary tract: a reappraisal of their classification after 20 years Surg. Clin. North Am. 82 2002 525 540, vi
161. W.H. Warren M. Welker P. Gattuso Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors Semin. Thorac. Cardiovasc. Surg. 18 2006 199 205
162. J.T. Watson N.H. Badner M.J. Ali The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease Can. J. Anaesth. 37 1990 798 800
163. G. Weckbecker U. Briner I. Lewis C. Bruns SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs Endocrinology 143 2002 4123 4130
164. R.A. Wermers V. Fatourechi A.G. Wynne L.K. Kvols R.V. Lloyd The glucagonoma syndrome. Clinical and pathologic features in 21 patients Medicine (Baltimore) 75 1996 53 63
165. A.N. Wymenga B. Eriksson P.I. Salmela M.B. Jacobsen E.J. Van Cutsem R.H. Fiasse M.J. Valimaki J. Renstrup E.G. de Vries K.E. Oberg Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms J. Clin. Oncol. 17 1999 1111
166. M.C. Zatelli D. Piccin M. Bondanelli F. Tagliati E. De Carlo M.D. Culler E.C. Uberti An in vivo OctreoScan-negative adrenal pheochromocytoma expresses somatostatin receptors and responds to somatostatin analogs treatment in vitro Horm. Metab. Res. 35 2003 349 354